Accelerating IL-38 research for anti-inflammatory breakthroughs
BioCurate’s Proof of Concept Fund is working to provide crucial support to address critical gaps in promising projects.
In the fast-paced world of medical research and drug development, innovative ideas often struggle to gain traction due to funding constraints. BioCurate’s Proof of Concept Fund is working to change this trend by providing crucial support to address critical gaps in promising projects, as exemplified by the groundbreaking work on Interleukin-38 (IL-38) led by Professor Claudia Nold from The Hudson Institute of Medical Research and Associate Professor Andrew Ellisdon from the Monash Biomedicine Discovery Institute.
IL-38, once an unsung hero in the cytokine world, has emerged as a potential game-changer in treating inflammatory diseases. Unlike its inflammatory counterparts in the interleukin family, IL-38 exhibits unique anti-inflammatory properties. However, researching this molecule posed challenges due to limited tools and its complex nature.
Professor Nold and Associate Professor Ellisdon, joined by experts from Monash University, including Professor Marcel Nold, Professor Eric Morand and Professor James Whisstock, embarked on a mission to uncover the mechanism of action (MOA) of their IL-38 mimicking molecule. This step is crucial in therapeutic development, as it ensures the highest standards of both safety and effectiveness.
BioCurate’s support came at a critical juncture, providing the resources needed to maintain momentum and recruit essential expertise within the team. This support ensures continuity in this vital research, offering reassurance that the successful development of their IL-38 candidate is within reach.
Beyond financial support, BioCurate’s involvement catalysed the project’s progress by connecting the team with contract research organisations. These collaborations facilitated validation and complementary experiments, contributing significantly to understanding the MOA.
“Seeing academic research translated into patient treatments is the ultimate goal, but it needs strong partnerships and support of the kind we receive from Biocurate,” said Professor Claudia Nold.
“In an increasingly competitive research landscape, BioCurate’s assistance has been instrumental in accelerating all aspects of the project,” said Associate Professor Andrew Ellisdon.
As the team moves forward with toxicology and efficacy studies, the potential for developing a new class of anti-inflammatory therapeutics looks promising.
GENERAL MEDIA ENQUIRIES
For more Monash media stories, visit our news and events site
Monash Media
E: media@monash.edu
T: +61 (0) 3 9903 4840
About BioCurate
Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate identifies promising biomedical research discoveries and manages their translation into high-quality pre-clinical candidates for novel human therapeutics. We operate in the under-resourced yet critical early phases of therapeutic development to drive early decisions and overcome common barriers to success.
BioCurate is operationally independent, with a team of experts who bring decades of scientific and commercial expertise. This expertise enables us to recognise and realise real-world potential and provides a critical bridge between academia and industry. With an extensive global network within the biotechnology sector, we are well-positioned to drive the most feasible commercial path forward for Australian innovations.
About the Monash Biomedicine Discovery Institute at Monash University
Committed to making discoveries that will relieve the future burden of disease, Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.
About the Hudson Institute of Medical Research
Hudson Institute of Medical Research is a leading Australian independent medical research institute, an affiliate of Monash University and Monash Health, and a partner in the Monash Health Translation Precinct (MHTP).
Based in Clayton, Melbourne, Australia, Hudson Institute’s world-class scientists are at the forefront of excellence in translational research, taking novel science-based treatments to the clinic to advance disease prevention, diagnosis and treatments. Our six specialist centres conduct cutting-edge research into cancer, infection and innate immunity, reproductive and baby health, genetic diseases and endocrinology.
Hudson Institute’s 75 years of research excellence and discovery include the development of current IVF technology, a range of antibodies, changes in practices for the prevention of SIDS, and the discovery of inhibin, leading to diagnostic tests for Down syndrome and some ovarian cancers.